{"doi":"10.1016/j.ajo.2016.08.022","title":"Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension","abstract":null,"journal":"American Journal of Ophthalmology","year":2016,"id":651464,"datarank":0.37273599746820013,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"self_citation_contribution":0.37273599746820013,"citation_network_contribution":0.0,"self_endowment_contribution":0.37273599746820013,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1618487,"name":"Toru Ikegami","orcid":"0000-0002-1642-9982","position":1,"is_corresponding":false},{"id":1699041,"name":"Yuji Ishikawa","orcid":"0000-0003-0084-2585","position":2,"is_corresponding":false},{"id":646557,"name":"Satoru Kikuchi","orcid":"0000-0002-7671-0696","position":3,"is_corresponding":false},{"id":1312685,"name":"Tetsuya Yamamoto","orcid":"0000-0001-9977-9373","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension","abstract":"<h4>Purpose</h4>To assess the intraocular pressure (IOP)-lowering effects and safety of a carteolol/latanoprost fixed combination drug (OPC-1085EL) vs latanoprost (Study 1) and carteolol (Study 2) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).<h4>Design</h4>Multicenter, randomized, evaluator-masked (Study 1)/double-masked (Study 2), parallel-group studies.<h4>Methods</h4>Setting: Twenty-eight clinical sites (Study 1) and 19 clinical sites (Study 2) in Japan.<h4>Study population</h4>Outpatients with bilateral POAG or OH whose predose IOP was 18 to <35 mm Hg in the study eye after 4 weeks' treatment with latanoprost (Study 1) or carteolol (Study 2) (defined as baseline).<h4>Intervention</h4>In Study 1, 237 patients applied OPC-1085EL (n = 118) or latanoprost (n = 119) for 8 weeks. In Study 2, 193 patients applied OPC-1085EL (n = 78), carteolol (n = 78), or carteolol/latanoprost concomitant therapy (n = 37) for 8 weeks.<h4>Main outcome measure</h4>Adjusted mean IOP reduction at predose from baseline to week 8.<h4>Results</h4>In Study 1, the adjusted mean IOP reductions (95% confidence interval [CI]) were 2.9 (2.5-3.3) mm Hg and 1.6 (1.2-2.0) mm Hg in the OPC-1085EL and latanoprost groups, respectively (P < .0001). In Study 2, the adjusted mean IOP reductions (95% CI) were 3.5 (3.1-3.9) mm Hg and 1.6 (1.2-2.0) mm Hg in the OPC-1085EL and carteolol groups, respectively (P < .0001). All adverse drug reactions of OPC-1085EL observed in both studies were mild in severity and only 1 patient in each study discontinued because of an adverse drug reaction.<h4>Conclusions</h4>OPC-1085EL is superior to latanoprost or carteolol alone in terms of lowering IOP, and was well tolerated.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"27565224","pmcid":null,"openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":null,"license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0002939416304068?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0002939416304068?httpAccept=text/plain","host_type":"publisher"},{"url":"http://www.ajo.com/article/S0002939416304068/pdf","host_type":"Unpaywall"}],"fields_of_study":[],"mesh_terms":["Humans","Ocular Hypertension","Glaucoma, Open-Angle","Carteolol","Prostaglandins F, Synthetic","Adrenergic beta-Antagonists","Antihypertensive Agents","Ophthalmic Solutions","Treatment Outcome","Drug Therapy, Combination","Retrospective Studies","Follow-Up Studies","Double-Blind Method","Intraocular Pressure","Dose-Response Relationship, Drug","Time Factors","Adult","Aged","Aged, 80 and over","Middle Aged","Female","Male","Young Adult","Latanoprost"],"keywords":[],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-10T09:39:16.867542Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}